Glycoprotein

Global H3N2 infection Drug Pipeline Landscape Report 2024: Insights on 15+ Companies and 20+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024

This report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape.
  • A detailed picture of the H3N2 infection pipeline landscape is provided which includes the disease overview and H3N2 infection treatment guidelines.
  • The assessment part of the report embraces, in depth H3N2 infection commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their H3N2 infection drug candidates in the most advanced stage, i.e.

Sugary handshakes are how cells talk to each other − understanding these name tags can clarify how the immune system works

Retrieved on: 
Thursday, February 8, 2024

Unlike people, cells perform these handshakes using the diverse range of sugar molecules coating their surface like trees covering a landscape.

Key Points: 
  • Unlike people, cells perform these handshakes using the diverse range of sugar molecules coating their surface like trees covering a landscape.
  • Handshakes between these sugar molecules, or glycans, trigger cells to react in specific ways toward each other, such as escape, ignore or destroy.

What are glycans?

  • The vast number of possible glycan structures that can be built from connecting these sugar molecules together allows glycans to store rich information.
  • Glycans are chemically bonded to proteins and lipids on the surface of red blood cells.
  • Notably, the surface of type A red blood cells have glycans that differ from the glycans on the surface of type B and type O red blood cells.
  • For example, distinctive glycoproteins cover the surface of the viruses that cause COVID-19, HIV and H1N1 influenza and help them infect cells.
  • Glycolipids also coat many bacteria, allowing them to stick to their hosts and protect them from viruses and immune cells.

How do cells read glycans?

  • Found on surfaces of certain immune cells, these lectins deliver the glycans to proteins on other immune cells that can now selectively destroy any viruses or cells that carry that glycan.
  • For example, these lectins recognize glycans on the surfaces of cancer cells and direct other immune cells to eliminate these cancer cells.
  • Another type of lectin called siglecs are found on surfaces of immune cells and help them distinguish self from nonself, that is, between the cells that make up the body and the cells that are foreign to the body.
  • The bacterial glycans in the vaccine trigger an immune response when immune cells recognize the glycans as foreign threats.

Examining every sugar molecule

  • Comprehensively extracting all the information stored in glycans is very difficult because there isn’t currently technology able to analyze the complex and diverse structures of glycans.
  • Individual glycans are composed of sugar molecules in unique arrangements, but current analytical tools can only simultaneously analyze many glycans.


My lab is confronting this challenge by developing imaging technology that can analyze the structure of glycans by imaging each individual molecule. Essentially, we’re developing a technique to open the jar and study every single candy one at a time. In the long run, my team aspires to unveil how these glycans present themselves to the proteins that recognize them and, finally, reveal the very language that cells use to express themselves.
Kelvin Anggara works for the Max Planck Institute for Solid State Research and receives funding from the European Research Council under Project GlycoX (101075996).

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Retrieved on: 
Thursday, December 21, 2023

CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued

Key Points: 
  • CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued
    PARIS, December 21, 2023.
  • Sanofi is discontinuing the global clinical development program of tusamitamab ravtansine.
  • An Independent Data Monitoring Committee (IDMC) found that tusamitamab ravtansine as a monotherapy did not meet its dual primary endpoint of progression-free survival (PFS) compared to docetaxel.
  • “Our team is grateful to the patients, families and healthcare professionals involved in the tusamitamab ravtansine development program.

Osmolality Analysis in Bioprocessing: From Theory to Practice, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, November 6, 2023

TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production. Osmolality is described as the measurement of the contribution of all the dissolved solutes to the osmotic pressure of a solution. In biopharma, osmolality is usually used as a critical quality control (QC) check for cell culture media, buffers and formulated drug products. It is also used as a critical process parameter during upstream cell culture and downstream filtration.

Key Points: 
  • Attendees will learn about using osmolality analysis in Chinese hamster ovary (CHO) cell health studies.
  • The featured speakers will discuss current uses and future potential for osmolality analysis at the upstream and downstream stages of bioprocessing.
  • TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production.
  • Join this webinar to gain insights into osmolality in correlation with IgG production in a media development project.

The MOG Project, Pediatric Neurologist Secure CDC Approval to Adopt ICD-10 Code for Rare Disease MOGAD

Retrieved on: 
Monday, October 2, 2023

OLNEY, Md., Oct. 2, 2023 /PRNewswire-PRWeb/ -- The MOG Project, a nonprofit organization committed to supporting the research and treatment of Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) announced that its Executive Director Julia Lefelar, with support from The MOG Project Executive Board and Children's Hospital Los Angeles (CHLA) Pediatric Neurologist Jonathan Santoro, MD, secured approval to have the US Centers for Disease Control and Prevention (CDC) create an ICD-10 code for MOGAD. As of October 1, 2023, an official code for MOGAD is included in the 10th edition of the International Classification of Diseases (ICD) and Related Health Problems, which is relied upon by physicians and insurance providers to classify diagnoses and advise treatment.

Key Points: 
  • Without a CDC code, MOGAD patients had previously been grouped in with patients with similar diseases like neuromyelitis optica spectrum disorder, optic neuritis, acute disseminated encephalomyelitis, transverse myelitis and even multiple sclerosis.
  • "For the MOGAD community, this CDC code is more than a win for better health outcomes and fewer insurance delays, it gives our rare disease an identity and legitimizes it."
  • "The addition of a MOGAD specific ICD-10 code allows patients to better access the therapies that they need to treat their disease," said Santoro.
  • "Further, it allows for disease monitoring across the country, which will increase knowledge and research on this rare neuroimmunology disorder."

MOBILion to Showcase Innovations in Separation Science - New Capabilities and Application Workflows at ASMS 2023

Retrieved on: 
Thursday, June 1, 2023

MOBILion's high-resolution ion mobility product, MOBIE®, provides the industry's highest resolution, full mass range, single pass ion mobility separation capability.

Key Points: 
  • MOBILion's high-resolution ion mobility product, MOBIE®, provides the industry's highest resolution, full mass range, single pass ion mobility separation capability.
  • In six seminar presentations, industry collaborators will present data demonstrating the unique ability to solve their analytical challenges with high-resolution ion mobility (HRIM-MS).
  • ASMS provides the perfect venue to share our latest advancements and foster collaborations that will drive innovation forward."
  • To obtain further details regarding MOBILion Systems' presence at ASMS 2023 and to register for the events, please visit: https://info.mobilionsystems.com/asms2023 .

InterVenn Demonstrates Power of Its GlycoVision™ Platform In Advanced Adenoma and Colorectal Cancer

Retrieved on: 
Monday, May 8, 2023

This data, generated by InterVenn’s novel, proprietary biomarker discovery platform, GlycoVision™ , analyzed 575 retrospective samples and was able to achieve an overall sensitivity of 89% and specificity of 89% for predicting advanced adenoma (AA) and colorectal cancer (CRC).

Key Points: 
  • This data, generated by InterVenn’s novel, proprietary biomarker discovery platform, GlycoVision™ , analyzed 575 retrospective samples and was able to achieve an overall sensitivity of 89% and specificity of 89% for predicting advanced adenoma (AA) and colorectal cancer (CRC).
  • Separately, AA (N=32) was predicted with 87.5% sensitivity and CRC with 89.4% sensitivity.
  • The sensitivity results of 87.5% for AA prediction is the highest that has been reported to date in the industry.
  • To put simply, we’ve known for some time of the possibility to detect AA at the pre-cancer stage,” said Daniel Hommes, MD, PhD, gastroenterologist, and Chief Medical Officer at InterVenn.

Nobel Laureate Prof. James Rothman and Drug Discovery Expert John Baldoni Join Gnubiotics as Senior Advisors

Retrieved on: 
Wednesday, May 3, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230504005132/en/
    Prof. James Rothman is one of the world's most distinguished biochemists.
  • John Baldoni is a renowned drug discovery and development expert, with extensive experience in all aspects of drug development, from basic research toscaleup and market authorization.
  • He served as the former Senior Vice President of Platform Technology and Science at GSK’s R&D Executive Team.
  • Mr. Baldoni brings a wealth of knowledge and experience to Gnubiotics, and his expertise will be invaluable in helping the company achieve its goals.

InterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023

Retrieved on: 
Wednesday, April 19, 2023

InterVenn Biosciences , the life science company pioneering glycoproteomics, today announced new clinical data that demonstrates the power of InterVenn’s proprietary biomarker discovery platform, GlycoVision™ , to detect advanced adenomas (AA) and colorectal cancer (CRC).

Key Points: 
  • InterVenn Biosciences , the life science company pioneering glycoproteomics, today announced new clinical data that demonstrates the power of InterVenn’s proprietary biomarker discovery platform, GlycoVision™ , to detect advanced adenomas (AA) and colorectal cancer (CRC).
  • The data will be presented as a “Poster of Distinction" at the 2023 Digestive Disease Week Conference (DDW), being held May 6-9, in Chicago, IL.
  • GlycoVision’s method of assessing circulating serum glycoproteins is unlike any non-invasive test for CRC that’s on the market, which primarily rely on circulating tumor DNA (ctDNA).
  • Details on the time and location of the presentation are as follows:
    Warning Signs from the Crypt: Circulating Aberrant Glycosylation Signatures Correlate with Advanced Adenoma and Colorectal Cancer

Global Lysosomal Disease Treatment Market Report 2022 to 2028: Featuring Pfizer, Takeda Pharmaceutical, Sanofi and Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023

The Global Lysosomal Disease Treatment Market size is expected to reach $11 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.

Key Points: 
  • The Global Lysosomal Disease Treatment Market size is expected to reach $11 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.
  • Lysosomal diseases (LSDs) are a complex group of metabolic disorders that are often inherited in an autosomal recessive manner.
  • The primary driving forces in the enzyme replacement therapy market are the expanding research and development for lysosomal disease diagnosis and drug development for treatment.
  • The increasing incidence of lysosomal disease will be a key factor contributing to the acceleration of the market's growth rate.